Time course of histological progression in primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would be helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo- controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
In the citing paper
“The median time to develop extensive fibrosis (≥F3) was 2 years.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [54]
In the citing paper
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [53]
Citations
Cites
The Jackknife, the Bootstrap and Other Resampling Plans
Efron, B. (1982) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9781611970319 · Cited by 8,120
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, O. (1997) · Population (French Edition) · doi:10.2307/1534625 · Cited by 2,884
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Nineteen Dubious Ways to Compute the Exponential of a Matrix
Moler, C., & Van Loan, C. (1978) · SIAM Review · doi:10.1137/1020098 · Cited by 1,526
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Self-citationElements of the theory of Markov processes and their applications
(1960) · Journal of the Franklin Institute · doi:10.1016/0016-0032(60)90686-4 · Cited by 731
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationBeneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., Altman, D. G., Popper, H., Portmann, B., Doniach, D., Ranek, L., Tygstrup, N., & Williams, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90213-6 · Cited by 423
Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417
A Prospective Trial of Colchicine for Primary Biliary Cirrhosis
Kaplan, M. M., Alling, D. W., Zimmerman, H. J., Wolfe, H. J., Sepersky, R. A., Hirsch, G. S., Elta, G. H., Glick, K. A., & Eagen, K. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152304 · Cited by 313
Christensen, E., Crowe, J., Doniach, D., Popper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 273
A Controlled Trial of Cyclosporine in the Treatment of Primary Biliary Cirrhosis
Wiesner, R. H., Ludwig, J., Lindor, K. D., Jorgensen, R. A., Baldus, W. P., Homburger, H. A., & Dickson, E. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005173222003 · Cited by 212
Self-citationTrial of Penicillamine in Advanced Primary Biliary Cirrhosis
Dickson, E. R., Fleming, T. R., Wiesner, R. H., Baldus, W. P., Fleming, C. R., Ludwig, J., & McCall, J. T. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504183121602 · Cited by 165
Self-citationA Prospective Controlled Trial of Azathioprine in Primary Biliary Cirrhosis
Heathcote, J., Ross, A., & Sherlock, S. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80250-8 · Cited by 159
Randomized trial of chlorambucil for primary biliary cirrhosis
Hoofnagle, J. H., Davis, G. L., Schafer, D. F., Peters, M., Avigan, M. I., Pappas, S. C., Hanson, R. G., Minuk, G. Y., Dusheiko, G. M., Campbell, G., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90183-6 · Cited by 157
Portmann, B. C., Pópper, H., Neuberger, J., & Williams, R. L. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90001-0 · Cited by 142
Evaluation of colchicine therapy in primary biliary cirrhosis
Bodenheimer, H. C., Schaffner, F., & Pezzullo, J. C. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90300-9 · Cited by 140
A Prospective Trial of D-Penicillamine in Primary Biliary Cirrhosis
Matloff, D. S., Alpert, E., Resnick, R. H., & Kaplan, M. M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198202113060602 · Cited by 125
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., et al. (1985) · Gastroenterology · doi:10.5555/uri:pii:0016508585902136 · Cited by 122
D-PENICILLAMINE TREATMENT IMPROVES SURVIVAL IN PRIMARY BILIARY CIRRHOSIS
Epstein, O., Lee, R., Boss, A. M. B., Jain, S., Cook, D. G., Scheuer, P., & Sherlock, S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92456-9 · Cited by 118
Treatment of primary biliary cirrhosis with low-dose weekly methotrexate
Kaplan, M. M., & Knox, T. A. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90085-y · Cited by 113
Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.
Neuberger, J., Christensen, E., Portmann, B., Caballeria, J., Rodes, J., Ranek, L., Tygstrup, N., & Williams, R. (1985) · Gut · doi:10.1136/gut.26.2.114 · Cited by 110
Grambsch, P. M., Dickson, R. E., Kaplan, M., Lesage, G., Fleming, T. R., & Langworthy, A. L. (1989) · Hepatology · doi:10.1002/hep.1840100516 · Cited by 107
Nonsuppurative destructive chronic cholangitis and chronic hepatitis.
Popper, H., & Schaffner, F. (1970) · PubMed · Cited by 93
Azathioprine in primary biliary cirrhosis: A preliminary report of an international trial
Crowe, J., Christensen, E., Smith, M. G. M., Cochrane, M. A. G., Ranek, L., Watkinson, G., Doniach, D., Pópper, H., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90784-2 · Cited by 88
A Prospective Clinical Trial of D–Penicillamine in the Treatment of Primary Biliary Cirrhosis
Bodenheimer, H. C., Schaffner, F., Sternlieb, I., Klion, F. M., Vernace, S., & Pezzullo, J. (1985) · Hepatology · doi:10.1002/hep.1840050613 · Cited by 60
Taal, B. G., Schalm, S. W., ten Kate, F. J. W., Henegouwen, G. P. V. B., & Brandt, K. ‐. (1983) · Liver International · doi:10.1111/j.1600-0676.1983.tb00887.x · Cited by 28
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2
Cited by
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citation
Metadata
- Authors
- Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Hepatology
- Published
- 1996-01
- Volume
- 23
- Issue
- 1
- Pages
- 52-56
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2112332162
- Cited by
- 184
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7183 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 34-238-07A1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- primary biliary cirrhosis, histological progression, histological staging, liver biopsy, D-penicillamine, Markov model, disease progression rate, histological regression, clinical trial design, treatment efficacy assessment
- MeSH terms
- Biopsy, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Markov Chains, Middle Aged, Penicillamine, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.